The Experts below are selected from a list of 243 Experts worldwide ranked by ideXlab platform
Robert H Mealey - One of the best experts on this subject based on the ideXlab platform.
-
Theileria equi isolates vary in susceptibility to Imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor
Parasites & Vectors, 2015Co-Authors: Siddra A Hines, Joshua D Ramsay, Lowell S Kappmeyer, Audrey Ot Lau, Kayode K Ojo, Wesley C Van Voorhis, Donald P Knowles, Robert H MealeyAbstract:Background The apicomplexan hemoparasite Theileria equi is a causative agent of equine piroplasmosis, eradicated from the United States in 1988. However, recent outbreaks have sparked renewed interest in treatment options for infected horses. Imidocarb dipropionate is the current drug of choice, however variation in clinical response to therapy has been observed. Methods We quantified the in vitro susceptibility of two T. equi isolates and a lab generated variant to both Imidocarb dipropionate and a bumped kinase inhibitor compound 1294. We also evaluated the capacity of in vitro Imidocarb dipropionate exposure to decrease susceptibility to that drug. The efficacy of Imidocarb dipropionate for clearing infection in four T. equi infected ponies was also assessed. Results We observed an almost four-fold difference in Imidocarb dipropionate susceptibility between two distinct isolates of T. equi . Four ponies infected with the less susceptible USDA Florida strain failed to clear the parasite despite two rounds of treatment. Importantly, a further 15-fold decrease in susceptibility was produced in this strain by continuous in vitro Imidocarb dipropionate exposure. Despite a demonstrated difference in Imidocarb dipropionate susceptibility, there was no difference in the susceptibility of two T. equi isolates to bumped kinase inhibitor 1294. Conclusions The observed variation in Imidocarb dipropionate susceptibility, further reduction in susceptibility caused by drug exposure in vitro , and failure to clear T. equi infection in vivo , raises concern for the emergence of drug resistance in clinical cases undergoing treatment. Bumped kinase inhibitors may be effective as alternative drugs for the treatment of resistant T. equi parasites.
-
Theileria equi isolates vary in susceptibility to Imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor.
Parasites & Vectors, 2015Co-Authors: Siddra A Hines, Joshua D Ramsay, Lowell S Kappmeyer, Audrey Ot Lau, Kayode K Ojo, Wesley C Van Voorhis, Donald P Knowles, Robert H MealeyAbstract:Background The apicomplexan hemoparasite Theileria equi is a causative agent of equine piroplasmosis, eradicated from the United States in 1988. However, recent outbreaks have sparked renewed interest in treatment options for infected horses. Imidocarb dipropionate is the current drug of choice, however variation in clinical response to therapy has been observed.
Siddra A Hines - One of the best experts on this subject based on the ideXlab platform.
-
Theileria equi isolates vary in susceptibility to Imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor
Parasites & Vectors, 2015Co-Authors: Siddra A Hines, Joshua D Ramsay, Lowell S Kappmeyer, Audrey Ot Lau, Kayode K Ojo, Wesley C Van Voorhis, Donald P Knowles, Robert H MealeyAbstract:Background The apicomplexan hemoparasite Theileria equi is a causative agent of equine piroplasmosis, eradicated from the United States in 1988. However, recent outbreaks have sparked renewed interest in treatment options for infected horses. Imidocarb dipropionate is the current drug of choice, however variation in clinical response to therapy has been observed. Methods We quantified the in vitro susceptibility of two T. equi isolates and a lab generated variant to both Imidocarb dipropionate and a bumped kinase inhibitor compound 1294. We also evaluated the capacity of in vitro Imidocarb dipropionate exposure to decrease susceptibility to that drug. The efficacy of Imidocarb dipropionate for clearing infection in four T. equi infected ponies was also assessed. Results We observed an almost four-fold difference in Imidocarb dipropionate susceptibility between two distinct isolates of T. equi . Four ponies infected with the less susceptible USDA Florida strain failed to clear the parasite despite two rounds of treatment. Importantly, a further 15-fold decrease in susceptibility was produced in this strain by continuous in vitro Imidocarb dipropionate exposure. Despite a demonstrated difference in Imidocarb dipropionate susceptibility, there was no difference in the susceptibility of two T. equi isolates to bumped kinase inhibitor 1294. Conclusions The observed variation in Imidocarb dipropionate susceptibility, further reduction in susceptibility caused by drug exposure in vitro , and failure to clear T. equi infection in vivo , raises concern for the emergence of drug resistance in clinical cases undergoing treatment. Bumped kinase inhibitors may be effective as alternative drugs for the treatment of resistant T. equi parasites.
-
Theileria equi isolates vary in susceptibility to Imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor.
Parasites & Vectors, 2015Co-Authors: Siddra A Hines, Joshua D Ramsay, Lowell S Kappmeyer, Audrey Ot Lau, Kayode K Ojo, Wesley C Van Voorhis, Donald P Knowles, Robert H MealeyAbstract:Background The apicomplexan hemoparasite Theileria equi is a causative agent of equine piroplasmosis, eradicated from the United States in 1988. However, recent outbreaks have sparked renewed interest in treatment options for infected horses. Imidocarb dipropionate is the current drug of choice, however variation in clinical response to therapy has been observed.
Ron Johnson - One of the best experts on this subject based on the ideXlab platform.
-
pharmacokinetics of Imidocarb dipropionate in white tailed deer odocoileus virginianus after single intramuscular administration
Journal of Veterinary Pharmacology and Therapeutics, 2020Co-Authors: Ellie L. Milnes, Pauline Delnatte, Murray R. Woodbury, Adam Hering, Sam Lee, Dale A. Smith, Nicole M. Nemeth, Ronette Gehring, Ron JohnsonAbstract:This study was designed to investigate the pharmacokinetics of Imidocarb, a carbanilide derivative, in white-tailed deer (Odocoileus virginianus). The pharmacokinetic properties of a single intramuscular (IM) dose of Imidocarb were determined in 10 deer. A single IM injection of 3.0 mg/kg Imidocarb dipropionate was administered, and blood samples were collected prior to, and up to 48 hr after Imidocarb administration. Plasma Imidocarb concentrations were determined by high-performance liquid chromatography with ultraviolet detection. The disposition of plasma Imidocarb was best characterized by a two-compartment open model. The mean ± SE maximal Imidocarb concentration in deer was 880.78 ± 81.12 ng/ml at 38.63 ± 5.30 min postinjection. The distribution phase had a half-life (t1/2α ) of 25.90 ± 10.21 min, and plasma Imidocarb concentration declined with a terminal elimination half-life (t1/2β ) of 464.06 ± 104.08 min (7.73 ± 1.73 hr). Apparent volume of distribution based on the terminal phase (VZ /F) was 9.20 ± 2.70 L/kg, and apparent total body clearance (Cl/F) was 15.97 ± 1.28 ml min-1 kg-1 .
-
Pharmacokinetics of Imidocarb dipropionate in white‐tailed deer (Odocoileus virginianus) after single intramuscular administration
Journal of Veterinary Pharmacology and Therapeutics, 2019Co-Authors: Ellie L. Milnes, Pauline Delnatte, Murray R. Woodbury, Adam Hering, Sam Lee, Dale A. Smith, Nicole M. Nemeth, Ronette Gehring, Ron JohnsonAbstract:This study was designed to investigate the pharmacokinetics of Imidocarb, a carbanilide derivative, in white-tailed deer (Odocoileus virginianus). The pharmacokinetic properties of a single intramuscular (IM) dose of Imidocarb were determined in 10 deer. A single IM injection of 3.0 mg/kg Imidocarb dipropionate was administered, and blood samples were collected prior to, and up to 48 hr after Imidocarb administration. Plasma Imidocarb concentrations were determined by high-performance liquid chromatography with ultraviolet detection. The disposition of plasma Imidocarb was best characterized by a two-compartment open model. The mean ± SE maximal Imidocarb concentration in deer was 880.78 ± 81.12 ng/ml at 38.63 ± 5.30 min postinjection. The distribution phase had a half-life (t1/2α ) of 25.90 ± 10.21 min, and plasma Imidocarb concentration declined with a terminal elimination half-life (t1/2β ) of 464.06 ± 104.08 min (7.73 ± 1.73 hr). Apparent volume of distribution based on the terminal phase (VZ /F) was 9.20 ± 2.70 L/kg, and apparent total body clearance (Cl/F) was 15.97 ± 1.28 ml min-1 kg-1 .
Donald P Knowles - One of the best experts on this subject based on the ideXlab platform.
-
Theileria equi isolates vary in susceptibility to Imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor
Parasites & Vectors, 2015Co-Authors: Siddra A Hines, Joshua D Ramsay, Lowell S Kappmeyer, Audrey Ot Lau, Kayode K Ojo, Wesley C Van Voorhis, Donald P Knowles, Robert H MealeyAbstract:Background The apicomplexan hemoparasite Theileria equi is a causative agent of equine piroplasmosis, eradicated from the United States in 1988. However, recent outbreaks have sparked renewed interest in treatment options for infected horses. Imidocarb dipropionate is the current drug of choice, however variation in clinical response to therapy has been observed. Methods We quantified the in vitro susceptibility of two T. equi isolates and a lab generated variant to both Imidocarb dipropionate and a bumped kinase inhibitor compound 1294. We also evaluated the capacity of in vitro Imidocarb dipropionate exposure to decrease susceptibility to that drug. The efficacy of Imidocarb dipropionate for clearing infection in four T. equi infected ponies was also assessed. Results We observed an almost four-fold difference in Imidocarb dipropionate susceptibility between two distinct isolates of T. equi . Four ponies infected with the less susceptible USDA Florida strain failed to clear the parasite despite two rounds of treatment. Importantly, a further 15-fold decrease in susceptibility was produced in this strain by continuous in vitro Imidocarb dipropionate exposure. Despite a demonstrated difference in Imidocarb dipropionate susceptibility, there was no difference in the susceptibility of two T. equi isolates to bumped kinase inhibitor 1294. Conclusions The observed variation in Imidocarb dipropionate susceptibility, further reduction in susceptibility caused by drug exposure in vitro , and failure to clear T. equi infection in vivo , raises concern for the emergence of drug resistance in clinical cases undergoing treatment. Bumped kinase inhibitors may be effective as alternative drugs for the treatment of resistant T. equi parasites.
-
Theileria equi isolates vary in susceptibility to Imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor.
Parasites & Vectors, 2015Co-Authors: Siddra A Hines, Joshua D Ramsay, Lowell S Kappmeyer, Audrey Ot Lau, Kayode K Ojo, Wesley C Van Voorhis, Donald P Knowles, Robert H MealeyAbstract:Background The apicomplexan hemoparasite Theileria equi is a causative agent of equine piroplasmosis, eradicated from the United States in 1988. However, recent outbreaks have sparked renewed interest in treatment options for infected horses. Imidocarb dipropionate is the current drug of choice, however variation in clinical response to therapy has been observed.
Wesley C Van Voorhis - One of the best experts on this subject based on the ideXlab platform.
-
Theileria equi isolates vary in susceptibility to Imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor
Parasites & Vectors, 2015Co-Authors: Siddra A Hines, Joshua D Ramsay, Lowell S Kappmeyer, Audrey Ot Lau, Kayode K Ojo, Wesley C Van Voorhis, Donald P Knowles, Robert H MealeyAbstract:Background The apicomplexan hemoparasite Theileria equi is a causative agent of equine piroplasmosis, eradicated from the United States in 1988. However, recent outbreaks have sparked renewed interest in treatment options for infected horses. Imidocarb dipropionate is the current drug of choice, however variation in clinical response to therapy has been observed. Methods We quantified the in vitro susceptibility of two T. equi isolates and a lab generated variant to both Imidocarb dipropionate and a bumped kinase inhibitor compound 1294. We also evaluated the capacity of in vitro Imidocarb dipropionate exposure to decrease susceptibility to that drug. The efficacy of Imidocarb dipropionate for clearing infection in four T. equi infected ponies was also assessed. Results We observed an almost four-fold difference in Imidocarb dipropionate susceptibility between two distinct isolates of T. equi . Four ponies infected with the less susceptible USDA Florida strain failed to clear the parasite despite two rounds of treatment. Importantly, a further 15-fold decrease in susceptibility was produced in this strain by continuous in vitro Imidocarb dipropionate exposure. Despite a demonstrated difference in Imidocarb dipropionate susceptibility, there was no difference in the susceptibility of two T. equi isolates to bumped kinase inhibitor 1294. Conclusions The observed variation in Imidocarb dipropionate susceptibility, further reduction in susceptibility caused by drug exposure in vitro , and failure to clear T. equi infection in vivo , raises concern for the emergence of drug resistance in clinical cases undergoing treatment. Bumped kinase inhibitors may be effective as alternative drugs for the treatment of resistant T. equi parasites.
-
Theileria equi isolates vary in susceptibility to Imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor.
Parasites & Vectors, 2015Co-Authors: Siddra A Hines, Joshua D Ramsay, Lowell S Kappmeyer, Audrey Ot Lau, Kayode K Ojo, Wesley C Van Voorhis, Donald P Knowles, Robert H MealeyAbstract:Background The apicomplexan hemoparasite Theileria equi is a causative agent of equine piroplasmosis, eradicated from the United States in 1988. However, recent outbreaks have sparked renewed interest in treatment options for infected horses. Imidocarb dipropionate is the current drug of choice, however variation in clinical response to therapy has been observed.
